June 12, 2025BMY: Bristol-Myers Squibb Co. Reports Positive Phase 3 Trial Results For Sotyktu ~1 min.Investors are taking notice of Bristol-Myers Squibb Company, as they have recently announced positive phase 3 trial results for their drug Sotyktu. This news has caused BMY shares to rise by 3....
May 14, 2025QuantWave Successfully Achieves Price Target Forecast for Bristol-Myers Squibb Company with 14.06% Profit ~2 min.QuantWave, an automated forecasting platform, recently celebrated a significant achievement in its analytics with the successful price target forecast for the stock of BRISTOL-MYERS SQUIBB COMPANY....
May 14, 2025BRISTOL-MYERS SQUIBB COMPANY Hits QuantWave Price Target with 13.0% Profit Margin ~2 min.On April 11, 2025, QuantWave, an automated forecasting platform, released a short signal for BRISTOL-MYERS SQUIBB COMPANY with a price target forecast of 44.12 $, indicating a 13....
May 8, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Price Target as QuantWave Forecast Achieves 7.55% Profit ~1 min.BRISTOL-MYERS SQUIBB COMPANY has seen its stock reach the predicted price target set by QuantWave's automated forecasting platform....
April 10, 2025BRISTOL-MYERS SQUIBB COMPANY Hits Forecast Target with 8.57% Profit: A Success Story for QuantWave ~2 min.BRISTOL-MYERS SQUIBB COMPANY (BMY) recently reached the price target forecasted by QuantWave, resulting in a profitable outcome for investors....
December 26, 2024Positive Results from Psoriatic Arthritis Trials Boost Bristol-Myers Squibb Stock ~1 min.Bristol-Myers Squibb Company (BMY), a leading pharmaceutical company, has recently announced positive topline results from two pivotal Phase 3 trials evaluating its drug Sotyktu deucravacitinib in adults with psoriatic arthritis. The trials have shown promising outcomes, with the drug meeting key endpoints and demonstrating effectiveness in treating the condition. Psoriatic arthritis is a chronic ...
February 27, 2025Eli Lilly and Company Acquires Organovos FXR Program in IBD Treatment Development ~1 min.Eli Lilly and Company has recently made headlines with its acquisition of Organovos FXR Program, a significant step towards advancing treatment options for Inflammatory Bowel Disease (IBD)....
December 29, 2024Bristol-Myers Squibb Makes Significant Progress in Psoriatic Arthritis Treatment ~1 min.Bristol-Myers Squibb Company, a leading pharmaceutical company, has announced promising results from two Phase 3 trials evaluating the effectiveness of its new drug, Sotyktu deucravacitinib, in treating psoriatic arthritis in adults. The trials have shown that Sotyktu hits key endpoints and provides positive outcomes for patients suffering from this debilitating condition. Institutional investors ...
March 14, 2025Johnson & Johnson's Decades-Long Quest for Effective IBD Treatments ~1 min.Johnson & Johnson has been investing in research and development for decades in order to find effective treatments for inflammatory bowel disease (IBD)....
January 5, 2025Regeneron Pharmaceuticals: A Strong Performer with Promising Financials ~2 min.Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) has been a steady performer in the biopharmaceutical industry, delivering a decent return of 89% for investors over the last five years....
